China coronavirus vaccine may be ready for public in November

Grant Boone
September 15, 2020

Bourla, however, said the availability of the COVID19 vaccine before 2020 would depend upon the safety data and approval from the United States regulator Food and Drug Administration (FDA).

In an interview with CBS, Bourla stated the company would know where it stands with its potential vaccine by the end of October.

Sinopharm said in July that its vaccine could be ready for public use by the end of this year after the conclusion of Phase 3 trials.

Also over the weekend, the pair said they have asked the FDA for the extra participants in order to include a broader patient population, and plans to include adolescents as young as 16 years of age and people with chronic, stable HIV (human immunodeficiency viruses), hepatitis C or hepatitis B infection to "provide additional safety and efficacy data".

The companies are expecting the results of the trials to be out by October 2020.

AstraZeneca COVID-19 vaccine trial in United States remains on hold
In India , over 30 vaccine candidates are in different stages of development, said Union Health Minister Harsh Vardhan on Monday. It was more important for Bourla that his scientists were able to work without any strings attached, he said.

China looks to prioritise frontline workers and high-risk populations in its fight against coronavirus as the country's top medical official has said that not everyone in China will need to get vaccinated against COVID-19.

Pfizer is one of three companies now in late-stage testing for a vaccine.

The vaccine candidate utilizes chemical messenger RNA to mimic the surface of the coronavirus and teach the immune system to recognize and neutralize it. Several vaccines have already begun phase 3 clinical trials in the US, including vaccine candidate AZD1222, co-invented by the University of Oxford and its spin-out company Vaccitech, vaccine candidate mRNA-1273, developed by the US National Institute of Allergy and Infectious Diseases (NIAID) and American biotechnology company Moderna, and vaccine candidate BNT162b2 or B2, developed by Pfizer/BioNTech.

Britain has struck agreements with a number of pharmaceutical firms developing vaccines against the novel coronavirus in order to ensure it has access to an effective innoculation, including BioNTech, Pfizer, Janssen pharmaceuticals and Novavax.

Other reports by

Discuss This Article